We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel iPad App Augurs Technologies to Come

By HospiMedica International staff writers
Posted on 07 Dec 2011
A novel app for the Apple (Cupertino, CA, USA) iPad 2 can determine heart rate and respiratory rate using the tablet camera to sense small changes in color and movement.

The Vital Signs Camera App uses the tablet camera to sense small changes in facial color, indicative of changes in blood flow, to determine actual heart rate. More...
Respiratory rate is determined using the tablet camera to track the movement of the chest during breathing. The technology was developed by Royal Philips Electronics (Amsterdam, The Netherlands) over a period of three years. Advanced algorithms were developed to extract multiple parameters from real time video images, drawing on in-house expertise in optics, video, and signal processing.

To ensure a good measurement, the iPad 2 should be placed on a stable surface in front of the person, who then positions his or her face and chest inside marked areas, remaining still during the measurement period. It is possible to switch from one-time measurement to continuous measurement and storage of the results; it is also possible share the results with your friends via Facebook, Twitter, or e-mail. The Vital Signs Camera App is not intended for diagnosis, clinical monitoring, or decision making, and the measurements and statistics are provided for entertainment purposes only.

“As long as you sit still and aren't wearing bulky clothing, it can figure out your vital signs in a few seconds with surprising accuracy,” wrote the digital journal MacNewsWorld in a review of the new app. “More than anything else, it may be more of a demonstration of technologies we'll soon be seeing used by actual medical pros.”

Related Links:
Royal Philips Electronics



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
New
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.